Twenty years. That’s how long Robert Oman has been cancer-free, thanks to a clinical trial offered at the University of Rochester’s Wilmot Cancer Institute. And he isn’t alone: 70% of patients in the trial who had advanced-stage follicular lymphoma survived at least 15 years after completing a standard treatment regimen of immunotherapy and a chemotherapy combination, known as CHOP.
This article was originally published on MedicalXpress.com

